The LungFit PH device was approved ini 2022 by the U.S. Food and Drug Administration and the European Union to treat PPHN.
An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...
A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...
Living with PH, it's easy to focus on what we can't do instead of what we can. Columnist Colleen Steele's advice? Don't limit ...
Body weight-adjusted Uptravi (selexipag) dosing for children and adolescents with pulmonary arterial hypertension (PAH) resulted in exposure to the treatment’s active ingredient comparable to that in ...
The U.S. FDA has provided advice for Tiakis Biotech's Phase 2 clinical trial of tiprelestat for pulmonary arterial hypertension, the company states.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback